Logos Global Management
Logos Global Management reported 59 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (7.5%), RVMD (7.4%) and IDYA (6.6%). Compared with Q2 2026, the fund opened new positions in MDGL, NBIX and AXSM, added to PRAX, IRON and ELVN, trimmed RVMD, IDYA and ERAS and sold out of CLDX, CMPS and MLYS.
Latest filing: what Logos Global Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PRAX Praxis Precision Medicines I | $124M | 7.5% | 425K | +165K (+63%) | 6 of 8 | |
| 2 | ![]() RVMD Revolution Medicines Inc | $123M | 7.4% | 600K | −100K (−14%) | 8 of 8 | |
| 3 | ![]() IDYA Ideaya Biosciences Inc | $109M | 6.6% | 2.9M | −150K (−5%) | 8 of 8 | |
| 4 | ![]() ERAS Erasca Inc | $86.5M | 5.2% | 5.9M | −6.3M (−51%) | 8 of 8 | |
| 5 | ![]() ABVX Abivax SA | $86.1M | 5.2% | 870K | −154K (−15%) | 5 of 8 | |
| 6 | ![]() CGON CG Oncology Inc | $69.1M | 4.2% | 975K | −25K (−3%) | 4 of 8 | |
| 7 | ![]() IRON Disc Medicine Inc | $66.4M | 4.0% | 1M | +140K (+16%) | 8 of 8 | |
| 8 | ![]() BNTX Biontech SE | $63.9M | 3.9% | 650K | −365K (−36%) | 4 of 8 | |
| 9 | ![]() TNGX Tango Therapeutics Inc | $53.6M | 3.2% | 2.1M | −700K (−25%) | 5 of 8 | |
| 10 | ![]() MDGL Madrigal Pharmaceuticals Inc | $50.4M | 3.0% | 100K | New position | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() CLDX Celldex Therapeutics Inc | $78.1M | 2.1M |
![]() CMPS Compass Pathways PLC | $31.8M | 2.3M |
![]() MLYS Mineralys Therapeutics Inc | $28.3M | 1.1M |
![]() REPL Replimune Group Inc | $27.7M | 2.5M |
![]() XENE Xenon Pharmaceuticals Inc | $27.2M | 450K |
🔒 Free account: see all 25.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() ERAS Erasca Inc | Call | $36.6M | 2.5M | +2,500,000 |
![]() AVTX Avalo Therapeutics Inc | Call | $23M | 1.5M | +1,500,000 |
![]() REPL Replimune Group Inc | Call | $19.9M | 1.5M | +1,500,000 |
![]() DSGN Design Therapeutics Inc | Call | $18.9M | 1.5M | +1,500,000 |
![]() SRPT Sarepta Therapeutics Inc | Call | $18.2M | 1M | +1,000,000 |
🔒 Free account: see all 13.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Logos Global Management 13F FAQ
What does Logos Global Management own?
Logos Global Management reported 59 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (7.5%), RVMD (7.4%) and IDYA (6.6%). The table above lists every position in the filing (the top 10 without an account).
What did Logos Global Management buy and sell in Q3 2026?
Compared with Q2 2026: 16 new positions, 10 added to, 24 trimmed and 25 sold out. New positions include MDGL, NBIX and AXSM. It sold all of CLDX, CMPS and MLYS.
When will Logos Global Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Logos Global Management's portfolio worth?
The Q3 2026 filing reports $1.7B in US stocks ($1.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.




























